Exploring the Relationship Between L-dopa Responsiveness and Small Intestinal Microbiome in Parkinson's Disease

Exclusion Criteria

• •1. Any risk of capsule non-excretion related to intercurrent gastrointestinal conditions.
• •2. Use of any medications in the week prior to the on-site study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function.
• •3. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration, e.g., SDQ score \> 4.
• •4. Any concomitant or previous treatment (\<2 months from on-site study visit) with significant anti-inflammatory or immune suppressant medication, e.g., DMARDs, biologicals or systemic corticosteroids, except non-chronic PRN use of an NSAID and/or 5-ASA (mesalazine) treatment.
• •5. Active cancer within 5 years.
• •6. Clinically significant immune deficiency (according to Investigator's judgement).
• •7. Antibiotic use (except for local use), ≤12 weeks prior to on-site study visit, or Fecal Microbiota Transplantation anytime in medical history.
• •8. Use of prebiotics, or probiotics ≤2 weeks prior to the on-site study visit.
• •9. Dementia in medical history.
• •10. Insulin-dependent diabetes mellitus.
• •11. Current Psychosis episode by clinical judgement based on anamnesis.
• •12. Pregnancy.
• •13. Alcohol or drug abuse.
• •14. Deep brain stimulation or Duodopa/Lecigon treatment.